Open | $1.910 |
Close | $1.770 |
Volume / Avg. | 197.804K / 48.614K |
Day Range | 1.750 - 2.050 |
52 Wk Range | 1.330 - 3.923 |
Market Cap | $31.023M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 45 |
Short Interest | % |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Exagen (NASDAQ: XGN) through any online brokerage.
Other companies in Exagen’s space includes: Fortress Biotech (NASDAQ:FBIO), Acurx Pharmaceuticals (NASDAQ:ACXP), OncoCyte (NASDAQ:OCX), Sensei Biotherapeutics (NASDAQ:SNSE) and Viracta Therapeutics (NASDAQ:VIRX).
The latest price target for Exagen (NASDAQ: XGN) was reported by Cantor Fitzgerald on Tuesday, September 26, 2023. The analyst firm set a price target for 6.00 expecting XGN to rise to within 12 months (a possible 229.67% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Exagen (NASDAQ: XGN) is $1.82 last updated March 18, 2024 at 7:37 PM EDT.
There are no upcoming dividends for Exagen.
Exagen’s Q1 earnings are confirmed for Monday, May 13, 2024.
There is no upcoming split for Exagen.
Exagen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.